Spectranetics' ThromCat XT
This article was originally published in The Gray Sheet
Firm's "next-generation" thrombus removal system debuts in Europe following receipt of CE mark approval, announced June 23. The single-use, disposable device, which helps remove thrombus from native coronary arteries and infra-inguinal arteries, offers enhanced thrombus removal and ease-of-use over the current ThromCat, the company explains. The European approval triggered a $1.5 million milestone payment to Kensey Nash under the terms of a previous development and regulatory services agreement, Spectranetics notes
You may also be interested in...
More patent-related turbulence appears ahead for Novartis’s sacubitril/valsartan combination in India, with Torrent emerging as the new challenger. The companies are engaged in a legal battle and the Indian firm is also seeking a revocation of the patent on the star heart failure treatment.
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Among the largest gaps in safety data is non-clinical research on CBD use's effect on developing fetus and adolescent brain, in utero/lactational exposure, reproductive toxicity and the potential for a latency period before toxicity, says FDA neuroscientist Andrew Shen.